Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors
about
GSK-3 as potential target for therapeutic intervention in cancerAdvances in targeting signal transduction pathwaysmiRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancersAnaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells.Modulation of sodium iodide symporter in thyroid cancerAnaplastic thyroid carcinomaActivating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Mouse models of thyroid cancer: A 2015 update.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineThe "Sharp" blade against HIF-mediated metastasis.p63 the guardian of human reproduction.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.Recent discoveries in the cycling, growing and aging of the p53 fieldMCM5 as a target of BET inhibitors in thyroid cancer cellsObesity and thyroid cancer: is leptin the (only) link?The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutationsObatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosisBlocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinomap53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancerThe STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular functions.Genetics and epigenetics of sporadic thyroid cancer.Modeling anaplastic thyroid carcinoma in the mouse.Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement.Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.Anaplastic Thyroid Carcinoma: A ceRNA Analysis Pointed to a Crosstalk between SOX2, TP53, and microRNA Biogenesis.Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerMolecular dynamics of the full-length p53 monomer.Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.SGK1 Is a Critical Component of an AKT-Independent Pathway Essential for PI3K-Mediated Tumor Development and Maintenance.TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients.Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion
P2860
Q27013811-BFE2DC1D-EEFA-4A17-A5A5-C2FDB8470034Q27686983-296B2E56-0410-4B76-B30F-89FB39051417Q28078451-EB69ABAE-D845-40D3-9841-20B0DD8878B4Q33914771-85BDE828-845B-4EB9-9B4D-81421C420249Q34119098-940C97F8-D66D-48EA-A6B6-035F5D3716A2Q34123525-2F409AF6-7C91-4B26-8DEE-6F0B0A8AB9FCQ34307356-C34ABB76-EB4F-40A5-B9B6-76A2AEA1AEC5Q34782086-B5E2869C-64F6-4156-9B87-BF06776D91EBQ35690173-EB3EA1AB-D210-41CF-BB0D-109B503550E3Q36075843-D93D443A-C181-4817-B68C-CA3B48490E53Q36255616-AA6552A5-3A00-44AB-B0AA-E8FE3A0B9E49Q36405539-4D9D37B2-28BB-41E5-8F3A-DB96BA4CF8F1Q36556350-4F81D7D0-ECCB-4384-B41B-98B4C18F58F6Q36581657-07458C62-8060-45A1-AFAF-B959752FC565Q36581663-D7BCFF07-77FD-4D52-B3F3-F1B2D73D916BQ36618604-CB330EB8-F35E-4974-9D34-F2EBB8CBE5C6Q36736358-CE1CB63D-B955-4236-8B7E-5537227AA017Q36965945-EB3BA129-F181-493C-88AD-031B3DF518AFQ37018589-4B83825D-67E9-4915-81FB-BB5D7BEF928EQ37199459-13B4EFF9-2DF0-48CA-B10D-CB671DE11296Q37376300-76874F62-9233-409B-A03E-047A2F89C138Q37680195-035E7C08-086D-45FE-ACA1-1FE525CD5FA4Q37712700-E174AF5F-42C4-4E35-80F7-50244FEE55B4Q37725293-AB921B1E-C95D-4C3A-A4F6-27C9AF6AF48CQ38026940-5EED6B8D-AACA-4B0E-ABDE-602D4BED8538Q38128097-E568FD7A-31FA-48E9-A6AB-0D752447078FQ38270915-09B5B39D-D5BC-489E-B3A8-EBCD81EA7FB7Q38581928-3C208611-B5C2-4E4E-A656-9DCDB31B22F5Q38719594-7D87462E-10C6-47DF-9BE3-45B347454D5AQ38907021-C987ED6E-E2E0-487C-940E-7BB3BDC09E08Q39328851-16A9BD25-7FEB-4910-92BC-65411280CFEEQ42039942-770EC7A4-B27D-493C-B7D3-58CC872B0438Q42103308-AD753291-D78F-44A6-B27A-1FFFF6A4D49CQ42256579-AA5DC310-A3F0-4737-89A4-97105FBFD3C6Q42540208-8B52F1A6-3A99-498F-A58F-5E7511677C57Q47621500-368DF0B2-0DD4-41B3-99EF-ED6BDF36D072Q52664598-248A3507-F4A6-474B-BEEB-E2E0860A1025Q54322019-AD87807C-44F7-47DC-85C0-420CE1FF6594Q55345025-66CA1EDA-19C9-467C-84A7-ED5BD7104EAFQ58701147-23ABBFB6-FFA8-454A-8520-36BD5059797D
P2860
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Thyrocyte-specific inactivatio ...... ly recapitulating human tumors
@en
Thyrocyte-specific inactivatio ...... y recapitulating human tumors.
@nl
type
label
Thyrocyte-specific inactivatio ...... ly recapitulating human tumors
@en
Thyrocyte-specific inactivatio ...... y recapitulating human tumors.
@nl
prefLabel
Thyrocyte-specific inactivatio ...... ly recapitulating human tumors
@en
Thyrocyte-specific inactivatio ...... y recapitulating human tumors.
@nl
P2093
P2860
P356
P1433
P1476
Thyrocyte-specific inactivatio ...... ly recapitulating human tumors
@en
P2093
Antonio Di Cristofano
Cristina Montagna
Florence Dasrath
Kristy S Kang
Mariavittoria Dima
Marika A Russo
Samuel Refetoff
Valeria G Antico Arciuch
Xiao-Hui Liao
P2860
P304
P356
10.18632/ONCOTARGET.380
P407
P577
2011-12-01T00:00:00Z